People · Operator
Named in public records as an officer, director or promoter · active 2009–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vascular Therapies Inc | — | Biotechnology | Series B | $89.2M | $471.9M | 2009 |
Samuel M. Liang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Samuel M. Liang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Somu Subramaniam | 1 | 17 |
| ROBERT CROCE | 1 | 7 |
| Andrew Midler | 1 | 6 |
| John McDermott | 1 | 5 |
| Daniel Ryan | 1 | 4 |
| Robert Flanagan | 1 | 4 |
| DAN RYAN | 1 | 4 |
| MICHAEL BAMBERGER | 1 | 3 |
| GERALD DORROS | 1 | 3 |
| SRIRAM IYER | 1 | 2 |
| ALLAN TESSLER | 1 | 2 |
| Sriram M. Iyer | 1 | 1 |
| Michael M. Bamberger | 1 | 1 |
| Paul M. Barkofsky | 1 | 1 |
| Robert M. Croce | 1 | 1 |
| Gerald M. Dorros | 1 | 1 |
| Somus Subramaniam | 1 | 1 |
| KIYOSHI TAKESUE | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.